toxoplasmosis cerebri (Toxoplasma gondii)
Advices
Priority | Medication | Remarks |
---|---|---|
Priority: 1st choice |
Medication: pyrimethamine po loading dose 200mg, 75mg 1dd 6 weeks +
sulfadiazine po 1500mg 4dd 6 weeks +
folinezuur po 15mg 1dd 6 weeks |
Remarks:
Bij gewicht <60kg:
|
Priority: 1st choice alternative |
Medication: cotrimoxazol (trimethoprim +sulfamethoxazol) po 30mg/kg 2dd 6 weeks |
|
Priority: 2nd choice |
Medication: pyrimethamine po loading dose 200mg, 75mg 1dd 6 weeks +
clindamycine iv 600mg 4dd 6 weeks +
folinezuur po 15mg 1dd 6 weeks |
Remarks:
|
Priority: 3rd choice |
Medication: pyrimethamine po loading dose 200mg, 75mg 1dd 6 weeks +
atovaquon po 1500mg 2dd 6 weeks +
folinezuur po 15mg 1dd 6 weeks |
Remarks:
|
Priority: 4th choice |
Medication: atovaquon po 1500mg 2dd 6 weeks |
Remarks:
|
Sources
-
Pubmed.gov publication # 23707647
Yan J, Huang B, Liu G, Wu B, Huang S, Zheng H, Shen J, Lun ZR, Wang Y, Lu F (2013) Meta-analysis of prevention and treatment of toxoplasmic encephalitis in HIV-infected patients. Acta Trop. 127(3):236-44.
-
Pubmed.gov publication # 9624473
Torre D, Casari S, Speranza F, Donisi A, Gregis G, Poggio A, Ranieri S, Orani A, Angarano G, Chiodo F, Fiori G, Carosi G (1998) Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group. Antimicrob Agents Chemother. 1998 Jun;42(6):1346-9.
-
https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/322/toxoplasma-gondii-encephalitis
U.S. Department of Health and Human Services "Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents"; Toxoplasma gondii Encephalitis
-
Pubmed.gov publication # 27353303
Hernandez AV et al. A systematic review and meta-analysis of the relative efficacy and safety of treatment regimens for HIV-associated cerebral toxoplasmosis: is trimethoprim-sulfamethoxazole a real option? HIV Med. 2017 Feb;18(2):115-124.
-
Pubmed.gov publication # 25714710
Jensen KDC, Camejo A, Melo MB, Cordeiro C, Julien L, Grotenbree GM, Frinckel EM, Ploegh HL, Young L, Saeij JPJ. Toxoplasma gondii superinfection and virulence during secondary infection correlate with the exact ROP5/ROP18 allelic combination. mBio. 2015;6(2).
-
Pubmed.gov publication # 30209035
Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice. Dunay IR, Gajurel K, Dhakal R, Liesenfeld O, Montoya JG.Clin Microbiol Rev. 2018 Sep 12;31(4):e00057-17.
Antimicrobial resources
The following antimicrobial agents have been used in these recommendations:
External antimicrobial resources
Menu position
Metadata
Swab vid: G-147497.11
Updated: 12/01/2023 - 17:25
Status: Published
General comments
Behandelduur:
bij immuuncompetente gastheer met ernstige symptomatische toxoplasmose is de behandelduur korter: 2-4 weken
Atovaquon: